Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
39 hedge funds and large institutions have $222M invested in Fusion Pharmaceuticals Inc. Common Shares in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 38 → 39 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
25% less capital invested
Capital invested by funds: $296M → $222M (-$74.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$1.81M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.08M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$394K |
| 4 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
+$297K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$283K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$1.51M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$390K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$270K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$166K |
FUSN Hedge Fund Activity: Q2 2021 in Review
39 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2021, worth a combined $222M — down 25% from $296M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new FUSN positions and 4 closed out — a net gain of 1 holder — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Artal Group, adding an estimated $1.81M. The largest seller was BlackRock, cutting an estimated $2.9M.
- 39 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2021, up from 38 in Q1 2021.
- Funds reported $222M of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2021, down 25% quarter-over-quarter.
- 5 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2021 and 4 closed out, a net change of +1 holder.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q2 2021 was Artal Group, an estimated $1.81M added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q2 2021 was BlackRock, an estimated $2.9M sold.
Based on aggregated 13F filings for Q2 2021.